Pulse 탐색 nav.journalClub 토론 트렌드 연구자

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

홈 탐색 nav.journalClub 트렌드

⌘+K

Bortezomib Treatment for Refractory PLA2R-Positive Membranous Nephropathy | Synapse

March 22, 2021Open Access

Bortezomib Treatment for Refractory PLA2R-Positive Membranous Nephropathy

AGAbdallah Sassine GearaUniversity of Pennsylvania VBVijay BhojHospital of the University of Pennsylvania JHJonathan J. HoganUniversity of Pennsylvania

Key Points

Key points are not available for this paper at this time.

Abstract

This case suggests that considering the source of PLA2R antibody production could lead to individualized and targeted therapies for MN.

AI에게 질문

Like

Bookmark

Share

View Full Paper

AI에게 질문

Like

Bookmark

Share

View Full Paper

Cite This Study

Geara et al. (Mon,) studied this question.

synapsesocial.com/papers/69dbc89537b5141e3ba3d404 https://doi.org/https://doi.org/10.1159/000515087

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Bortezomib as a Novel Approach to Early Recurrent Membranous Glomerulonephritis After Kidney Transplant Refractory to Combined Conventional Rituximab Therapy.2017 · 26 citations
2Rituximab in Idiopathic Membranous Nephropathy2012 · 325 citations
3Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness2020 · 51 citations
4The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy2020 · 241 citations
5Immunological remission in PLA2R-antibody–associated membranous nephropathy: cyclophosphamide versus rituximab2018 · 87 citations